approved glp 1 agonists GLP-1 receptor The Landscape Of GLP-1 Receptor

doi: 10.1038/nm919

Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment

10.1038/nm1196-1254 [DOI] [PubMed] [Google Scholar] Shan Y., Gao X., Zhao K., Xu C., Li H., Hu Y., et al

Additionally, the safety and tolerability profiles of GLP-1RAs have been well-established

In the GLP-1RA family of agents, the results of CVOT have been inconsistent

Clinical trials are underway to test these preliminary signals and determine whether GLP-1 analogs can reduce symptoms for people with depression, schizophrenia, addiction, and bipolar disorderalong with neurological conditions like Alzheimers disease and Parkinsons disease